APO Research
Talk to an analyst

APO RESEARCH · REPORT

Secondary Progressive Multiple Sclerosis Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Secondary Progressive Multiple Sclerosis Drug Market Outlook and Growth Opportunities 2026

19 December 2025200 pages

Choose your research edition.

Industry ResearchSecondary Progressive Multiple Sclerosis Drug Industry Research Report 2026137 pages · $2,950 USDIndustry Growth & TrendsGlobal Secondary Progressive Multiple Sclerosis Drug Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Secondary Progressive Multiple Sclerosis Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Secondary Progressive Multiple Sclerosis Drug Market Outlook and Growth Opportunities 2026200 pages · $4,250 USDMarket Analysis & ForecastGlobal Secondary Progressive Multiple Sclerosis Drug Market Analysis and Forecast 2026-2032206 pages · $4,950 USD

Market perspective

The global Secondary Progressive Multiple Sclerosis Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Secondary Progressive Multiple Sclerosis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Secondary Progressive Multiple Sclerosis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Secondary Progressive Multiple Sclerosis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Secondary Progressive Multiple Sclerosis Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Secondary Progressive Multiple Sclerosis Drug market include AB Science SA, Actelion Ltd, F. Hoffmann-La Roche Ltd., Genzyme Corporation, Glialogix, Inc., Immune Response BioPharma, Inc., Innate Immunotherapeutics Ltd, Kyorin Pharmaceutical Co., Ltd. and Mallinckrodt Plc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Secondary Progressive Multiple Sclerosis Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Secondary Progressive Multiple Sclerosis Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Secondary Progressive Multiple Sclerosis Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Secondary Progressive Multiple Sclerosis Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Secondary Progressive Multiple Sclerosis Drug Segment by Company

AB Science SA

Actelion Ltd

F. Hoffmann-La Roche Ltd.

Genzyme Corporation

Glialogix, Inc.

Immune Response BioPharma, Inc.

Innate Immunotherapeutics Ltd

Kyorin Pharmaceutical Co., Ltd.

Mallinckrodt Plc

MedDay SA

MedImmune, LLC

Merck KGaA

Meta-IQ ApS

Opexa Therapeutics, Inc.

Xenetic Biosciences (UK) Limited

Biogen, Inc.

Novartis AG

Secondary Progressive Multiple Sclerosis Drug Segment by Type

Etomoxir

Inebilizumab

IB-MS

GLX-1112

DC-TAB

Others

Secondary Progressive Multiple Sclerosis Drug Segment by Application

Hospital

Clinic

Others

Secondary Progressive Multiple Sclerosis Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Secondary Progressive Multiple Sclerosis Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Secondary Progressive Multiple Sclerosis Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Secondary Progressive Multiple Sclerosis Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Secondary Progressive Multiple Sclerosis Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Secondary Progressive Multiple Sclerosis Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Secondary Progressive Multiple Sclerosis Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Secondary Progressive Multiple Sclerosis Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Secondary Progressive Multiple Sclerosis Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Secondary Progressive Multiple Sclerosis Drug industry.

Chapter 3: Detailed analysis of Secondary Progressive Multiple Sclerosis Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Secondary Progressive Multiple Sclerosis Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Secondary Progressive Multiple Sclerosis Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Secondary Progressive Multiple Sclerosis Drug Industry Trends Table 2. Secondary Progressive Multiple Sclerosis Drug Industry Drivers Table 3. Secondary Progressive Multiple Sclerosis Drug Industry Opportunities and Challenges Table 4. Secondary Progressive Multiple Sclerosis Drug Industry Restraints Table 5. Global Secondary Progressive Multiple Sclerosis Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Secondary Progressive Multiple Sclerosis Drug Revenue Share by Company (2021-2026) Table 7. Global Secondary Progressive Multiple Sclerosis Drug Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Secondary Progressive Multiple Sclerosis Drug Sales Volume Share by Company (2021-2026) Table 9. Global Secondary Progressive Multiple Sclerosis Drug Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Secondary Progressive Multiple Sclerosis Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Secondary Progressive Multiple Sclerosis Drug Key Company Manufacturing Base & Headquarters Table 12. Global Secondary Progressive Multiple Sclerosis Drug Company, Product Type & Application Table 13. Global Secondary Progressive Multiple Sclerosis Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Secondary Progressive Multiple Sclerosis Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Etomoxir Table 18. Significant Companies of Inebilizumab Table 19. Significant Companies of IB-MS Table 20. Significant Companies of GLX-1112 Table 21. Significant Companies of DC-TAB Table 22. Significant Companies of Others Table 23. Global Secondary Progressive Multiple Sclerosis Drug Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Secondary Progressive Multiple Sclerosis Drug Sales Volume by Type (2021-2026) & (K Units) Table 25. Global Secondary Progressive Multiple Sclerosis Drug Sales Volume by Type (2027-2032) & (K Units) Table 26. Global Secondary Progressive Multiple Sclerosis Drug Sales Volume Share by Type (2021-2026) Table 27. Global Secondary Progressive Multiple Sclerosis Drug Sales Volume Share by Type (2027-2032) Table 28. Global Secondary Progressive Multiple Sclerosis Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Secondary Progressive Multiple Sclerosis Drug Sales Value by Type (2021-2026) & (US$ Million) Table 30. Global Secondary Progressive Multiple Sclerosis Drug Sales Value by Type (2027-2032) & (US$ Million) Table 31. Global Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type (2021-2026) Table 32. Global Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type (2027-2032) Table 33. Significant Companies of Hospital Table 34. Significant Companies of Clinic Table 35. Significant Companies of Others Table 36. Global Secondary Progressive Multiple Sclerosis Drug Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Secondary Progressive Multiple Sclerosis Drug Sales Volume by Application (2021-2026) & (K Units) Table 38. Global Secondary Progressive Multiple Sclerosis Drug Sales Volume by Application (2027-2032) & (K Units) Table 39. Global Secondary Progressive Multiple Sclerosis Drug Sales Volume Share by Application (2021-2026) Table 40. Global Secondary Progressive Multiple Sclerosis Drug Sales Volume Share by Application (2027-2032) Table 41. Global Secondary Progressive Multiple Sclerosis Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 42. Global Secondary Progressive Multiple Sclerosis Drug Sales Value by Application (2021-2026) & (US$ Million) Table 43. Global Secondary Progressive Multiple Sclerosis Drug Sales Value by Application (2027-2032) & (US$ Million) Table 44. Global Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application (2021-2026) Table 45. Global Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application (2027-2032) Table 46. Global Secondary Progressive Multiple Sclerosis Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 47. Global Secondary Progressive Multiple Sclerosis Drug Sales by Region (2021-2026) & (K Units) Table 48. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Region (2021-2026) Table 49. Global Secondary Progressive Multiple Sclerosis Drug Sales by Region (2027-2032) & (K Units) Table 50. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Region (2027-2032) Table 51. Global Secondary Progressive Multiple Sclerosis Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 52. Global Secondary Progressive Multiple Sclerosis Drug Sales Value by Region (2021-2026) & (US$ Million) Table 53. Global Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Region (2021-2026) Table 54. Global Secondary Progressive Multiple Sclerosis Drug Sales Value by Region (2027-2032) & (US$ Million) Table 55. Global Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Region (2027-2032) Table 56. Global Secondary Progressive Multiple Sclerosis Drug Market Average Price (US$/Unit) by Region (2021-2026) Table 57. Global Secondary Progressive Multiple Sclerosis Drug Market Average Price (US$/Unit) by Region (2027-2032) Table 58. Global Secondary Progressive Multiple Sclerosis Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 59. Global Secondary Progressive Multiple Sclerosis Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Secondary Progressive Multiple Sclerosis Drug Sales by Country (2021-2026) & (K Units) Table 61. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Country (2021-2026) Table 62. Global Secondary Progressive Multiple Sclerosis Drug Sales by Country (2027-2032) & (K Units) Table 63. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Country (2027-2032) Table 64. Global Secondary Progressive Multiple Sclerosis Drug Sales Value by Country (2021-2026) & (US$ Million) Table 65. Global Secondary Progressive Multiple Sclerosis Drug Sales Value Market Share by Country (2021-2026) Table 66. Global Secondary Progressive Multiple Sclerosis Drug Sales Value by Country (2027-2032) & (US$ Million) Table 67. Global Secondary Progressive Multiple Sclerosis Drug Sales Value Market Share by Country (2027-2032) Table 68. AB Science SA Company Information Table 69. AB Science SA Business Overview Table 70. AB Science SA Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. AB Science SA Secondary Progressive Multiple Sclerosis Drug Product Portfolio Table 72. AB Science SA Recent Development Table 73. Actelion Ltd Company Information Table 74. Actelion Ltd Business Overview Table 75. Actelion Ltd Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Actelion Ltd Secondary Progressive Multiple Sclerosis Drug Product Portfolio Table 77. Actelion Ltd Recent Development Table 78. F. Hoffmann-La Roche Ltd. Company Information Table 79. F. Hoffmann-La Roche Ltd. Business Overview Table 80. F. Hoffmann-La Roche Ltd. Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. F. Hoffmann-La Roche Ltd. Secondary Progressive Multiple Sclerosis Drug Product Portfolio Table 82. F. Hoffmann-La Roche Ltd. Recent Development Table 83. Genzyme Corporation Company Information Table 84. Genzyme Corporation Business Overview Table 85. Genzyme Corporation Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Genzyme Corporation Secondary Progressive Multiple Sclerosis Drug Product Portfolio Table 87. Genzyme Corporation Recent Development Table 88. Glialogix, Inc. Company Information Table 89. Glialogix, Inc. Business Overview Table 90. Glialogix, Inc. Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Glialogix, Inc. Secondary Progressive Multiple Sclerosis Drug Product Portfolio Table 92. Glialogix, Inc. Recent Development Table 93. Immune Response BioPharma, Inc. Company Information Table 94. Immune Response BioPharma, Inc. Business Overview Table 95. Immune Response BioPharma, Inc. Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Immune Response BioPharma, Inc. Secondary Progressive Multiple Sclerosis Drug Product Portfolio Table 97. Immune Response BioPharma, Inc. Recent Development Table 98. Innate Immunotherapeutics Ltd Company Information Table 99. Innate Immunotherapeutics Ltd Business Overview Table 100. Innate Immunotherapeutics Ltd Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Innate Immunotherapeutics Ltd Secondary Progressive Multiple Sclerosis Drug Product Portfolio Table 102. Innate Immunotherapeutics Ltd Recent Development Table 103. Kyorin Pharmaceutical Co., Ltd. Company Information Table 104. Kyorin Pharmaceutical Co., Ltd. Business Overview Table 105. Kyorin Pharmaceutical Co., Ltd. Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Kyorin Pharmaceutical Co., Ltd. Secondary Progressive Multiple Sclerosis Drug Product Portfolio Table 107. Kyorin Pharmaceutical Co., Ltd. Recent Development Table 108. Mallinckrodt Plc Company Information Table 109. Mallinckrodt Plc Business Overview Table 110. Mallinckrodt Plc Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Mallinckrodt Plc Secondary Progressive Multiple Sclerosis Drug Product Portfolio Table 112. Mallinckrodt Plc Recent Development Table 113. MedDay SA Company Information Table 114. MedDay SA Business Overview Table 115. MedDay SA Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. MedDay SA Secondary Progressive Multiple Sclerosis Drug Product Portfolio Table 117. MedDay SA Recent Development Table 118. MedImmune, LLC Company Information Table 119. MedImmune, LLC Business Overview Table 120. MedImmune, LLC Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. MedImmune, LLC Secondary Progressive Multiple Sclerosis Drug Product Portfolio Table 122. MedImmune, LLC Recent Development Table 123. Merck KGaA Company Information Table 124. Merck KGaA Business Overview Table 125. Merck KGaA Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. Merck KGaA Secondary Progressive Multiple Sclerosis Drug Product Portfolio Table 127. Merck KGaA Recent Development Table 128. Meta-IQ ApS Company Information Table 129. Meta-IQ ApS Business Overview Table 130. Meta-IQ ApS Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 131. Meta-IQ ApS Secondary Progressive Multiple Sclerosis Drug Product Portfolio Table 132. Meta-IQ ApS Recent Development Table 133. Opexa Therapeutics, Inc. Company Information Table 134. Opexa Therapeutics, Inc. Business Overview Table 135. Opexa Therapeutics, Inc. Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 136. Opexa Therapeutics, Inc. Secondary Progressive Multiple Sclerosis Drug Product Portfolio Table 137. Opexa Therapeutics, Inc. Recent Development Table 138. Xenetic Biosciences (UK) Limited Company Information Table 139. Xenetic Biosciences (UK) Limited Business Overview Table 140. Xenetic Biosciences (UK) Limited Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 141. Xenetic Biosciences (UK) Limited Secondary Progressive Multiple Sclerosis Drug Product Portfolio Table 142. Xenetic Biosciences (UK) Limited Recent Development Table 143. Biogen, Inc. Company Information Table 144. Biogen, Inc. Business Overview Table 145. Biogen, Inc. Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 146. Biogen, Inc. Secondary Progressive Multiple Sclerosis Drug Product Portfolio Table 147. Biogen, Inc. Recent Development Table 148. Novartis AG Company Information Table 149. Novartis AG Business Overview Table 150. Novartis AG Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 151. Novartis AG Secondary Progressive Multiple Sclerosis Drug Product Portfolio Table 152. Novartis AG Recent Development Table 153. Key Raw Materials Table 154. Raw Materials Key Suppliers Table 155. Secondary Progressive Multiple Sclerosis Drug Distributors List Table 156. Secondary Progressive Multiple Sclerosis Drug Customers List Table 157. Research Programs/Design for This Report Table 158. Authors List of This Report Table 159. Secondary Sources Table 160. Primary Sources List of Figures Figure 1. Secondary Progressive Multiple Sclerosis Drug Product Image Figure 2. Global Secondary Progressive Multiple Sclerosis Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Secondary Progressive Multiple Sclerosis Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Secondary Progressive Multiple Sclerosis Drug Sales (2021-2032) & (K Units) Figure 5. Global Secondary Progressive Multiple Sclerosis Drug Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Secondary Progressive Multiple Sclerosis Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Etomoxir Image Figure 10. Inebilizumab Image Figure 11. IB-MS Image Figure 12. GLX-1112 Image Figure 13. DC-TAB Image Figure 14. Others Image Figure 15. Global Secondary Progressive Multiple Sclerosis Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 16. Global Secondary Progressive Multiple Sclerosis Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 17. Global Secondary Progressive Multiple Sclerosis Drug Sales Volume Share by Type (2021-2032) Figure 18. Global Secondary Progressive Multiple Sclerosis Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Secondary Progressive Multiple Sclerosis Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type (2021-2032) Figure 21. Hospital Image Figure 22. Clinic Image Figure 23. Others Image Figure 24. Global Secondary Progressive Multiple Sclerosis Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global Secondary Progressive Multiple Sclerosis Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 26. Global Secondary Progressive Multiple Sclerosis Drug Sales Volume Share by Application (2021-2032) Figure 27. Global Secondary Progressive Multiple Sclerosis Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Secondary Progressive Multiple Sclerosis Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 29. Global Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application (2021-2032) Figure 30. Global Secondary Progressive Multiple Sclerosis Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 31. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 32. Global Secondary Progressive Multiple Sclerosis Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 33. Global Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 34. North America Secondary Progressive Multiple Sclerosis Drug Sales Value (2021-2032) & (US$ Million) Figure 35. North America Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Europe Secondary Progressive Multiple Sclerosis Drug Sales Value (2021-2032) & (US$ Million) Figure 37. Europe Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Sales Value (2021-2032) & (US$ Million) Figure 39. Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 40. South America Secondary Progressive Multiple Sclerosis Drug Sales Value (2021-2032) & (US$ Million) Figure 41. South America Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 42. Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Sales Value (2021-2032) & (US$ Million) Figure 43. Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 44. USA Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. USA Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. USA Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Canada Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Canada Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Canada Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Mexico Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Mexico Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Mexico Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Germany Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Germany Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Germany Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. France Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. France Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. France Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. U.K. Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. U.K. Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. U.K. Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Italy Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Italy Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Italy Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Spain Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Spain Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Spain Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Russia Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Russia Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Russia Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Netherlands Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Netherlands Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Netherlands Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Nordic Countries Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Nordic Countries Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Nordic Countries Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. China Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. China Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. China Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Japan Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Japan Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Japan Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. South Korea Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. South Korea Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. South Korea Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. India Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. India Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. India Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Australia Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Australia Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Australia Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Southeast Asia Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Southeast Asia Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Southeast Asia Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Brazil Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Brazil Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Brazil Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Argentina Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Argentina Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Argentina Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Chile Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Chile Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Chile Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Colombia Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Colombia Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Colombia Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Peru Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Peru Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Peru Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Saudi Arabia Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Saudi Arabia Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Israel Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Israel Arabia Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Israel Arabia Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. UAE Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. UAE Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. UAE Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Turkey Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Turkey Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Turkey Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Iran Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Iran Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Iran Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Egypt Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 126. Egypt Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 127. Egypt Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 128. Secondary Progressive Multiple Sclerosis Drug Value Chain Figure 129. Manufacturing Cost Structure Figure 130. Secondary Progressive Multiple Sclerosis Drug Sales Mode & Process Figure 131. Direct Comparison with Distribution Share Figure 132. Distributors Profiles Figure 133. Years Considered Figure 134. Research Process Figure 135. Key Executives Interviewed

Scope & coverage.

Types
  • Etomoxir
  • Inebilizumab
  • IB-MS
  • GLX-1112
  • DC-TAB
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • AB Science SA
  • Actelion Ltd
  • F. Hoffmann-La Roche Ltd.
  • Genzyme Corporation
  • Glialogix, Inc.
  • Immune Response BioPharma, Inc.
  • Innate Immunotherapeutics Ltd
  • Kyorin Pharmaceutical Co., Ltd.
  • Mallinckrodt Plc
  • MedDay SA
  • MedImmune, LLC
  • Merck KGaA
  • Meta-IQ ApS
  • Opexa Therapeutics, Inc.
  • Xenetic Biosciences (UK) Limited
  • Biogen, Inc.
  • Novartis AG

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Secondary Progressive Multiple Sclerosis Drug Sales Value (2021-2032)
  4. 1.2.2 Global Secondary Progressive Multiple Sclerosis Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Secondary Progressive Multiple Sclerosis Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Secondary Progressive Multiple Sclerosis Drug Market Dynamics
  1. 2.1 Secondary Progressive Multiple Sclerosis Drug Industry Trends
  2. 2.2 Secondary Progressive Multiple Sclerosis Drug Industry Drivers
  3. 2.3 Secondary Progressive Multiple Sclerosis Drug Industry Opportunities and Challenges
  4. 2.4 Secondary Progressive Multiple Sclerosis Drug Industry Restraints
3 Secondary Progressive Multiple Sclerosis Drug Market by Company
  1. 3.1 Global Secondary Progressive Multiple Sclerosis Drug Company Revenue Ranking in 2025
  2. 3.2 Global Secondary Progressive Multiple Sclerosis Drug Revenue by Company (2021-2026)
  3. 3.3 Global Secondary Progressive Multiple Sclerosis Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Secondary Progressive Multiple Sclerosis Drug Average Price by Company (2021-2026)
  5. 3.5 Global Secondary Progressive Multiple Sclerosis Drug Company Ranking (2024-2026)
  6. 3.6 Global Secondary Progressive Multiple Sclerosis Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Secondary Progressive Multiple Sclerosis Drug Company Product Type and Application
  8. 3.8 Global Secondary Progressive Multiple Sclerosis Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Secondary Progressive Multiple Sclerosis Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Secondary Progressive Multiple Sclerosis Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Secondary Progressive Multiple Sclerosis Drug Market by Type
  1. 4.1 Secondary Progressive Multiple Sclerosis Drug Type Introduction
  2. 4.1.1 Etomoxir
  3. 4.1.2 Inebilizumab
  4. 4.1.3 IB-MS
  5. 4.1.4 GLX-1112
  6. 4.1.5 DC-TAB
  7. 4.1.6 Others
  8. 4.2 Global Secondary Progressive Multiple Sclerosis Drug Sales Volume by Type
  9. 4.2.1 Global Secondary Progressive Multiple Sclerosis Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Secondary Progressive Multiple Sclerosis Drug Sales Volume by Type (2021-2032)
  11. 4.2.3 Global Secondary Progressive Multiple Sclerosis Drug Sales Volume Share by Type (2021-2032)
  12. 4.3 Global Secondary Progressive Multiple Sclerosis Drug Sales Value by Type
  13. 4.3.1 Global Secondary Progressive Multiple Sclerosis Drug Sales Value by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Secondary Progressive Multiple Sclerosis Drug Sales Value by Type (2021-2032)
  15. 4.3.3 Global Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type (2021-2032)
5 Secondary Progressive Multiple Sclerosis Drug Market by Application
  1. 5.1 Secondary Progressive Multiple Sclerosis Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Secondary Progressive Multiple Sclerosis Drug Sales Volume by Application
  6. 5.2.1 Global Secondary Progressive Multiple Sclerosis Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Secondary Progressive Multiple Sclerosis Drug Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Secondary Progressive Multiple Sclerosis Drug Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Secondary Progressive Multiple Sclerosis Drug Sales Value by Application
  10. 5.3.1 Global Secondary Progressive Multiple Sclerosis Drug Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Secondary Progressive Multiple Sclerosis Drug Sales Value by Application (2021-2032)
  12. 5.3.3 Global Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application (2021-2032)
6 Secondary Progressive Multiple Sclerosis Drug Regional Sales and Value Analysis
  1. 6.1 Global Secondary Progressive Multiple Sclerosis Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Secondary Progressive Multiple Sclerosis Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Secondary Progressive Multiple Sclerosis Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Secondary Progressive Multiple Sclerosis Drug Sales by Region (2027-2032)
  5. 6.3 Global Secondary Progressive Multiple Sclerosis Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Secondary Progressive Multiple Sclerosis Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Secondary Progressive Multiple Sclerosis Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Secondary Progressive Multiple Sclerosis Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Secondary Progressive Multiple Sclerosis Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Secondary Progressive Multiple Sclerosis Drug Sales Value (2021-2032)
  12. 6.6.2 North America Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Secondary Progressive Multiple Sclerosis Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Secondary Progressive Multiple Sclerosis Drug Sales Value (2021-2032)
  21. 6.9.2 South America Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Country, 2025 VS 2032
7 Secondary Progressive Multiple Sclerosis Drug Country-level Sales and Value Analysis
  1. 7.1 Global Secondary Progressive Multiple Sclerosis Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Secondary Progressive Multiple Sclerosis Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Secondary Progressive Multiple Sclerosis Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Secondary Progressive Multiple Sclerosis Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Secondary Progressive Multiple Sclerosis Drug Sales by Country (2027-2032)
  6. 7.4 Global Secondary Progressive Multiple Sclerosis Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Secondary Progressive Multiple Sclerosis Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Secondary Progressive Multiple Sclerosis Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Secondary Progressive Multiple Sclerosis Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Secondary Progressive Multiple Sclerosis Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 AB Science SA
  2. 8.1.1 AB Science SA Company Information
  3. 8.1.2 AB Science SA Business Overview
  4. 8.1.3 AB Science SA Secondary Progressive Multiple Sclerosis Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 AB Science SA Secondary Progressive Multiple Sclerosis Drug Product Portfolio
  6. 8.1.5 AB Science SA Recent Developments
  7. 8.2 Actelion Ltd
  8. 8.2.1 Actelion Ltd Company Information
  9. 8.2.2 Actelion Ltd Business Overview
  10. 8.2.3 Actelion Ltd Secondary Progressive Multiple Sclerosis Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Actelion Ltd Secondary Progressive Multiple Sclerosis Drug Product Portfolio
  12. 8.2.5 Actelion Ltd Recent Developments
  13. 8.3 F. Hoffmann-La Roche Ltd.
  14. 8.3.1 F. Hoffmann-La Roche Ltd. Company Information
  15. 8.3.2 F. Hoffmann-La Roche Ltd. Business Overview
  16. 8.3.3 F. Hoffmann-La Roche Ltd. Secondary Progressive Multiple Sclerosis Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 F. Hoffmann-La Roche Ltd. Secondary Progressive Multiple Sclerosis Drug Product Portfolio
  18. 8.3.5 F. Hoffmann-La Roche Ltd. Recent Developments
  19. 8.4 Genzyme Corporation
  20. 8.4.1 Genzyme Corporation Company Information
  21. 8.4.2 Genzyme Corporation Business Overview
  22. 8.4.3 Genzyme Corporation Secondary Progressive Multiple Sclerosis Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Genzyme Corporation Secondary Progressive Multiple Sclerosis Drug Product Portfolio
  24. 8.4.5 Genzyme Corporation Recent Developments
  25. 8.5 Glialogix, Inc.
  26. 8.5.1 Glialogix, Inc. Company Information
  27. 8.5.2 Glialogix, Inc. Business Overview
  28. 8.5.3 Glialogix, Inc. Secondary Progressive Multiple Sclerosis Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Glialogix, Inc. Secondary Progressive Multiple Sclerosis Drug Product Portfolio
  30. 8.5.5 Glialogix, Inc. Recent Developments
  31. 8.6 Immune Response BioPharma, Inc.
  32. 8.6.1 Immune Response BioPharma, Inc. Company Information
  33. 8.6.2 Immune Response BioPharma, Inc. Business Overview
  34. 8.6.3 Immune Response BioPharma, Inc. Secondary Progressive Multiple Sclerosis Drug Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Immune Response BioPharma, Inc. Secondary Progressive Multiple Sclerosis Drug Product Portfolio
  36. 8.6.5 Immune Response BioPharma, Inc. Recent Developments
  37. 8.7 Innate Immunotherapeutics Ltd
  38. 8.7.1 Innate Immunotherapeutics Ltd Company Information
  39. 8.7.2 Innate Immunotherapeutics Ltd Business Overview
  40. 8.7.3 Innate Immunotherapeutics Ltd Secondary Progressive Multiple Sclerosis Drug Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Innate Immunotherapeutics Ltd Secondary Progressive Multiple Sclerosis Drug Product Portfolio
  42. 8.7.5 Innate Immunotherapeutics Ltd Recent Developments
  43. 8.8 Kyorin Pharmaceutical Co., Ltd.
  44. 8.8.1 Kyorin Pharmaceutical Co., Ltd. Company Information
  45. 8.8.2 Kyorin Pharmaceutical Co., Ltd. Business Overview
  46. 8.8.3 Kyorin Pharmaceutical Co., Ltd. Secondary Progressive Multiple Sclerosis Drug Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Kyorin Pharmaceutical Co., Ltd. Secondary Progressive Multiple Sclerosis Drug Product Portfolio
  48. 8.8.5 Kyorin Pharmaceutical Co., Ltd. Recent Developments
  49. 8.9 Mallinckrodt Plc
  50. 8.9.1 Mallinckrodt Plc Company Information
  51. 8.9.2 Mallinckrodt Plc Business Overview
  52. 8.9.3 Mallinckrodt Plc Secondary Progressive Multiple Sclerosis Drug Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Mallinckrodt Plc Secondary Progressive Multiple Sclerosis Drug Product Portfolio
  54. 8.9.5 Mallinckrodt Plc Recent Developments
  55. 8.10 MedDay SA
  56. 8.10.1 MedDay SA Company Information
  57. 8.10.2 MedDay SA Business Overview
  58. 8.10.3 MedDay SA Secondary Progressive Multiple Sclerosis Drug Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 MedDay SA Secondary Progressive Multiple Sclerosis Drug Product Portfolio
  60. 8.10.5 MedDay SA Recent Developments
  61. 8.11 MedImmune, LLC
  62. 8.11.1 MedImmune, LLC Company Information
  63. 8.11.2 MedImmune, LLC Business Overview
  64. 8.11.3 MedImmune, LLC Secondary Progressive Multiple Sclerosis Drug Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 MedImmune, LLC Secondary Progressive Multiple Sclerosis Drug Product Portfolio
  66. 8.11.5 MedImmune, LLC Recent Developments
  67. 8.12 Merck KGaA
  68. 8.12.1 Merck KGaA Company Information
  69. 8.12.2 Merck KGaA Business Overview
  70. 8.12.3 Merck KGaA Secondary Progressive Multiple Sclerosis Drug Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Merck KGaA Secondary Progressive Multiple Sclerosis Drug Product Portfolio
  72. 8.12.5 Merck KGaA Recent Developments
  73. 8.13 Meta-IQ ApS
  74. 8.13.1 Meta-IQ ApS Company Information
  75. 8.13.2 Meta-IQ ApS Business Overview
  76. 8.13.3 Meta-IQ ApS Secondary Progressive Multiple Sclerosis Drug Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Meta-IQ ApS Secondary Progressive Multiple Sclerosis Drug Product Portfolio
  78. 8.13.5 Meta-IQ ApS Recent Developments
  79. 8.14 Opexa Therapeutics, Inc.
  80. 8.14.1 Opexa Therapeutics, Inc. Company Information
  81. 8.14.2 Opexa Therapeutics, Inc. Business Overview
  82. 8.14.3 Opexa Therapeutics, Inc. Secondary Progressive Multiple Sclerosis Drug Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Opexa Therapeutics, Inc. Secondary Progressive Multiple Sclerosis Drug Product Portfolio
  84. 8.14.5 Opexa Therapeutics, Inc. Recent Developments
  85. 8.15 Xenetic Biosciences (UK) Limited
  86. 8.15.1 Xenetic Biosciences (UK) Limited Company Information
  87. 8.15.2 Xenetic Biosciences (UK) Limited Business Overview
  88. 8.15.3 Xenetic Biosciences (UK) Limited Secondary Progressive Multiple Sclerosis Drug Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Xenetic Biosciences (UK) Limited Secondary Progressive Multiple Sclerosis Drug Product Portfolio
  90. 8.15.5 Xenetic Biosciences (UK) Limited Recent Developments
  91. 8.16 Biogen, Inc.
  92. 8.16.1 Biogen, Inc. Company Information
  93. 8.16.2 Biogen, Inc. Business Overview
  94. 8.16.3 Biogen, Inc. Secondary Progressive Multiple Sclerosis Drug Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Biogen, Inc. Secondary Progressive Multiple Sclerosis Drug Product Portfolio
  96. 8.16.5 Biogen, Inc. Recent Developments
  97. 8.17 Novartis AG
  98. 8.17.1 Novartis AG Company Information
  99. 8.17.2 Novartis AG Business Overview
  100. 8.17.3 Novartis AG Secondary Progressive Multiple Sclerosis Drug Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Novartis AG Secondary Progressive Multiple Sclerosis Drug Product Portfolio
  102. 8.17.5 Novartis AG Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Secondary Progressive Multiple Sclerosis Drug Value Chain Analysis
  2. 9.1.1 Secondary Progressive Multiple Sclerosis Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Secondary Progressive Multiple Sclerosis Drug Sales Mode & Process
  6. 9.2 Secondary Progressive Multiple Sclerosis Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Secondary Progressive Multiple Sclerosis Drug Distributors
  9. 9.2.3 Secondary Progressive Multiple Sclerosis Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst